Certain cancers show different effects at particular interfaces, such as TP53-TP53BP2, which is predicted to be strongly disabled in low grade glioma and weakly disabled in hepatocellular carcinoma owing to different mutational preferences of the principal contacting residues (Fig. 3a,b). Here, TP53 is linked to central nervous system cancer.